Weight ManagementGLOWNCT07829016
GLP-1 Impacts on Weight Management
An observational study of Weight Management and Disordered Eating Behaviors, run by University of California, San Francisco at 1 site in United States.
Trial summary
The goal of this observational study is to learn about the long-term effects of GLP-1RAs (Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound) in adolescents and young adults aged 12-21 who will start taking this drug for weight management. Read more about this study
- Who is it for?
- Ages 12 to 21 years
- Conditions the study is for
- Weight Management, Disordered Eating Behaviors
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Oct 2026to 1 Sep 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Participants will be 12-21 years olds who plan to begin GLP-1RA treatment for weight management. Participants will be current patients receiving care from UCSF affiliated clinics.
Who may be able to join
- Able to understand and provide informed consent or, for minor participants, able to provide assent with parent/guardian informed consent
- Age 12 and 21 years at the time of consent
- Able to read and write in English; for minor participants, at least one parent/guardian must be able to read and write in English or Spanish
- Willing and able to complete all required in-person and remote study visits and procedures
- Current binge-eating symptomatology
- Initiating first-time GLP-1RA therapy or related incretin-based therapy for weight management (Ozempic, Rybelsus, Wegovy)
Show all 10Show fewer
- Meets current FDA medication eligibility criteria for prescribed GLP-1RA treatment for weight management: BMI ≥95th percentile OR ≥85th percentile with ≥1 weight-related comorbidity for those <18 years old and a BMI>30 or BMI>26 with ≥1 weight-related comorbidity for those 18 years old and older
- Has reliable access to prescribed GLP1-RA medication through insurance coverage, self-payment, or discount pharmacy plans and is willing to take it as prescribed for the duration of study participation
- On a stable regimen of permitted concomitant medications for at least 1 month prior to GLP-1RA initiation. Participants recently taking prohibited medications may be eligible after an adequate wash-out period as applicable (minimum of 5 half-lives).
- Receiving care in a clinic affiliated with the research study
Who cannot join
- Current use of Lisdexamfetamine (Vyvanse) or insufficient washout from such medication prior to GLP-1RA initiation
- Anticipated medication changes or planned surgical procedures during the study period that, in the investigator's judgment, could affect study participation of interpretation of outcomes
- Known genetic metabolic or endocrine syndromes associated with obesity, including Prader Willi Syndrome and familial hypercholesterolemia
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Type 1 or type 2 diabetes
- History of pancreatitis
Show all 12Show fewer
- Documented uncontrolled thyroid disease
- History of bariatric surgery
- Current pregnancy or known plans to become pregnant within the next 6 months
- Suicidality or any suicide attempts within the past 3 months
- Current severe depressive symptoms at screening
- Any medical, psychiatric, behavioral, or other condition, disorder, or circumstance not otherwise specified in the exclusion criteria that, in the investigator's judgment, may compromise participant safety, study participation, or adherence to the protocol
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of California San Francisco, Mission Bay Campus
San Francisco, California, 94158
Marissa Raymond-Flesch, MD/MPH, 415-353-2747, GLOWStudy@ucsf.edu
Marissa Raymond-Flesch, MD
About this study
Official title: GLP-1 Longitudinal Outcomes in Weight Management
The goal of this observational study is to learn about the long-term effects of GLP-1RAs (Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound) in adolescents and young adults aged 12-21 who will start taking this drug for weight management. The main question it aims to answer is:
How does starting GLP-1RAs impact eating behaviors and mental health symptoms?
Participants starting to take GLP-1RAs as part of their medical care for weight management will answer online survey questions about their experience taking the drug for 1 year.
Read the detailed description
This prospective single-arm observational study will enroll 100 adolescents and young adults 12 to 21 years of age who are initiating a prescribed glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy or related incretin-based therapy for weight management. The study will assess longitudinal changes in eating behaviors and related clinical features from pre-treatment baseline through 6 months of GLP-1RA treatment, spanning treatment initiation, titration, and maintenance. Exploratory cognitive assessments and biomarker collection will examine behavioral and biological correlates of change. After 6 months, participants will be in follow-up and attend a final study visit at their 12-month mark.
- Conditions
- Weight Management, Disordered Eating Behaviors
- Keywords
- GLP-1RAs, Weight Management
- Medical subject headings
- Disordered Eating Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adolescents and Young Adults (12-21) | Adolescents and Young Adults who plan to start GLP-1RA treatment for weight management. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the frequency of Objective Binge Episodes
Change in the frequency of OBEs over the past 28 days from baseline to 6 months following GLP-1RA initiation, as measured by the Eating Disorder Examination (EDE) Binge-Eating Module
Measured: 6 months
Secondary outcomes (7)
Change in Frequency of LOC Episodes
Change in the frequency of LOC episodes over the past 28 days from baseline to 6 months following GLP-1RA initiation, as measured by a single-item question (key secondary endpoint)
Measured: Baseline to 6 months
Change in Frequency of OBEs
Change in the frequency of OBEs over the past 28 days from baseline to 4 months following GLP-1RA initiation, as measured by the EDE Binge-Eating Module
Measured: From baseline to 4 months
Change in Frequency of LOC Episodes
Change in the frequency of LOC episodes over the past 28 days from baseline to 4 months following GLP-1RA initiation, as measured by a single-item question
Measured: Baseline to 4 months
Change in Disordered Eating Symptom Severity
Change in overall disordered eating symptom severity over the past 28 days from baseline to 4 and 6 months following GLP-1RA initiation, as measured by the Eating Disorder Examination-Questionnaire (EDE-Q) Global score (range: 0-6; higher scores indicate greater eating-disorder psychopathology).
Measured: Baseline to 4-6 months
Change in Body Esteem
Change in body esteem from baseline to 4 and 6 months following GLP-1RA initiation, as measured by the Body Esteem Scale for Adolescents and Adults (BESAA) (subscale score range: 0-4; higher scores indicate greater body esteem).
Measured: Baseline to Month 4 and 6
Change in Food Noise
Change in food noise from baseline to 4 and 6 months following GLP-1RA initiation, as measured by the Food Noise Questionnaire (FNQ) Total score (total score range: 0-20; higher scores indicate greater food noise).
Measured: Baseline to 4 and 6 months
Change in Frequency on Purging Behaviors
Change in the frequency of purging behaviors over the past 28 days from baseline to 4 and 6 months following GLP-1RA initiation, as measured by the Eating Disorder Examination Questionnaire (EDE-Q) Global Score: (range: 0-6; higher scores indicate greater eating-disorder psychopathology).
Measured: Baseline to 4 and 6 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start20 Oct 2026 (estimated)
- Primary completion1 Sep 2029 (estimated)
- Study completion1 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Weight ManagementStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Marissa Raymond-Flesch, MD, MPH, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07829016
- Sponsor's protocol ID
- STUDY00000173
- Acronym
- GLOW
- Status last verified
- Oct 2026
- First submitted
- 14 Sep 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GLP-1 Longitudinal Outcomes in Weight Management
- ClinicalTrials.gov ID
- NCT07829016
- Acronym / sponsor ID
- GLOW / STUDY00000173
- Conditions
- Weight Management, Disordered Eating Behaviors
- Keywords
- GLP-1RAs, Weight Management
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 20 Oct 2026 (estimated)
- Primary completion
- 1 Sep 2029 (estimated)
- Study completion
- 1 Sep 2029 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the long-term effects of GLP-1RAs (Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound) in adolescents and young adults aged 12-21 who will start taking this drug for weight management. The main question it aims to answer is:
How does starting GLP-1RAs impact eating behaviors and mental health symptoms?
Participants starting to take GLP-1RAs as part of their medical care for weight management will answer online survey questions about their experience taking the drug for 1 year.
Detailed description
This prospective single-arm observational study will enroll 100 adolescents and young adults 12 to 21 years of age who are initiating a prescribed glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy or related incretin-based therapy for weight management. The study will assess longitudinal changes in eating behaviors and related clinical features from pre-treatment baseline through 6 months of GLP-1RA treatment, spanning treatment initiation, titration, and maintenance. Exploratory cognitive assessments and biomarker collection will examine behavioral and biological correlates of change. After 6 months, participants will be in follow-up and attend a final study visit at their 12-month mark.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adolescents and Young Adults (12-21) | – | –Adolescents and Young Adults who plan to start GLP-1RA treatment for weight management. |
Who may qualify
- Ages
- 12 to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Participants will be 12-21 years olds who plan to begin GLP-1RA treatment for weight management. Participants will be current patients receiving care from UCSF affiliated clinics.
Key inclusion criteria (10 listed)
- Able to understand and provide informed consent or, for minor participants, able to provide assent with parent/guardian informed consent
- Age 12 and 21 years at the time of consent
- Able to read and write in English; for minor participants, at least one parent/guardian must be able to read and write in English or Spanish
- Willing and able to complete all required in-person and remote study visits and procedures
- Current binge-eating symptomatology
Key exclusion criteria (12 listed)
- Current use of Lisdexamfetamine (Vyvanse) or insufficient washout from such medication prior to GLP-1RA initiation
- Anticipated medication changes or planned surgical procedures during the study period that, in the investigator's judgment, could affect study participation of interpretation of outcomes
- Known genetic metabolic or endocrine syndromes associated with obesity, including Prader Willi Syndrome and familial hypercholesterolemia
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Type 1 or type 2 diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in the frequency of Objective Binge Episodes
Time frame: 6 months
Change in the frequency of OBEs over the past 28 days from baseline to 6 months following GLP-1RA initiation, as measured by the Eating Disorder Examination (EDE) Binge-Eating Module
7 secondary outcomes
Change in Frequency of LOC Episodes
Time frame: Baseline to 6 months
Change in Frequency of OBEs
Time frame: From baseline to 4 months
Change in Frequency of LOC Episodes
Time frame: Baseline to 4 months
Change in Disordered Eating Symptom Severity
Time frame: Baseline to 4-6 months
Change in Body Esteem
Time frame: Baseline to Month 4 and 6
Change in Food Noise
Time frame: Baseline to 4 and 6 months
Change in Frequency on Purging Behaviors
Time frame: Baseline to 4 and 6 Months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Weight Management
Enrolling by invitationObservational study
Sustaining Health After an Intensive Weight-loss Pro-gramme
Obesity & Overweight, Weight Loss
Active, not recruiting
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
Overweight, Obesity
RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
Chronic Weight Management
RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
Chronic Weight Management
RecruitingPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marissa Raymond-Flesch, MD, MPH principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Weight Management and Disordered Eating Behaviors, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marissa Raymond-Flesch, MD (4153532747 ext. (416) 562-7034, glowstudy@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the frequency of Objective Binge Episodes (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026; AzTrials last refreshed its copy on 29 Oct 2026.